The decrease of complication rate in hypertensives: Benefits of combined antihypertensive treatment by Perindopril and Amlodipine (adapted from the materials from the Annual Scientific Meeting of the European Society of Hypertension [ESH], 2011)
https://doi.org/10.18705/1607-419X-2011-17-4-372-378
Abstract
Effective blood pressure (BP) control remains a key factor in the reduction of cardiovascular morbidity and mortality. Main criteria of choice of rational antihypertensive therapy include optimal antihypertensive effect and documented reduction of the risk of cardiovascular events and mortality. On 18th June, 2011, at the European Meeting on Hypertension and Cardiovascular Prevention, the symposium «Is hypertension a fatal disease today?» was held with discussions on the effective antihypertensive therapy in hypertensive patients using fixed-dose combination of perindopril and amlodipine (Prestance). This treatment can be recommended as preferable for hypertensive patients with uncontrolled BP, with high risk of complications, with diabetes mellitus and coronary heart disease.
About the Authors
Y. A. Karpov
The Russian Cardiology Research and Production Complex of the Ministry of Health and Social Development of the Russian Federation, Moscow
Russian Federation
Russian Federation
A. T. Shubina
The Russian Cardiology Research and Production Complex of the Ministry of Health and Social Development of the Russian Federation, Moscow
Russian Federation
Russian Federation
References
1. Lawes C.M <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lawes%20CM%22%5BAuthor%5D>., Vander Hoorn S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Vander%20Hoorn%20S%22%5BAuthor%5D>., Rodgers A <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Rodgers%20A%22%5BAuthor%5D>; International Society of Hypertension <http://www.ncbi.nlm.nih.gov/pubmed?term=%22International%20Society%20of%20Hypertension%22%5BCorporate%20Author%5D>. Global burden of blood-pressure-related disease, 2001 // Lancet. <http://www.ncbi.nlm.nih.gov/pubmed?term=Lawes%2C%20Hoorn%20Lancet%202008%3B%20371%3A%201513-1518> - 2008. - Vol. 371, № 9623. - P. 1513-1518.
2.
3. Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke, and coronary heart disease. Part 2: Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context // Lancet. - 1990. - Vol. 335, № 8693. - P. 827-838.
4.
5. Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Eur. Heart J <http://www.ncbi.nlm.nih.gov/pubmed?term=European%20Heart%20J%202007%3B%2028%2812%29%3A%201462-1526>. - 2007. - Vol. 28, № 12. - P. 1462-1536.
6.
7. Hansson L., Zanchetti J.A., Carruthers S.G. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial // Lancet. - 1998. - Vol. 351, № 9118. - P. 1756 -1762.
8.
9. Bahl V.K <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bahl%20VK%22%5BAuthor%5D>., Jadhav U.M <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Jadhav%20UM%22%5BAuthor%5D>., Thacker H.P <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Thacker%20HP%22%5BAuthor%5D>. Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice: results from the STRONG prospective, observational, multicenter study // Am. J. Cardiovasc. Drugs <http://www.ncbi.nlm.nih.gov/pubmed/19463019>. - 2009. - Vol. 9, № 3. - P. 135-142.
10.
11. Dahlцf B <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Dahl%C3%B6f%20B%22%5BAuthor%5D>., Sever P.S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Sever%20PS%22%5BAuthor%5D>., Poulter N.R <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Poulter%20NR%22%5BAuthor%5D>. et al.; ASCOT Investigators <http://www.ncbi.nlm.nih.gov/pubmed?term=%22ASCOT%20Investigators%22%5BCorporate%20Author%5D>. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial // Lancet. <http://www.ncbi.nlm.nih.gov/pubmed?term=Dahl%C3%B6f%20Lancet%202005%3B%20366%3A%20895-906> - 2005. - Vol. 366, № 9489. - P. 895-906.
12.
13. Rothwell P.M <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Rothwell%20PM%22%5BAuthor%5D>., Howard S.C <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Howard%20SC%22%5BAuthor%5D>., Dolan E <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Dolan%20E%22%5BAuthor%5D>. et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension // Lancet <http://www.ncbi.nlm.nih.gov/pubmed?term=Rothwell%20AND%20Lancet%202010%3B%20375%289718%29%3A%20895-905>. - 2010. - Vol. 375, № 9718. - P. 895-905.
14.
15. Rothwell P.M <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Rothwell%20PM%22%5BAuthor%5D>., Howard S.C <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Howard%20SC%22%5BAuthor%5D>., Dolan E <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Dolan%20E%22%5BAuthor%5D>. et al.; ASCOT-BPLA and MRC Trial Investigators <http://www.ncbi.nlm.nih.gov/pubmed?term=%22ASCOT-BPLA%20and%20MRC%20Trial%20Investigators%22%5BCorporate%20Author%5D>. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke // Lancet Neurol <http://www.ncbi.nlm.nih.gov/pubmed?term=Rothwell%20AND%20Lancet%20Neurol%202010%3B%209%285%29%3A%20469-480>. - 2010. - Vol. 9, № 5. - P. 469-480.
16.
17. Perloff D <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Perloff%20D%22%5BAuthor%5D>., Sokolow M <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Sokolow%20M%22%5BAuthor%5D>., Cowan R <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Cowan%20R%22%5BAuthor%5D>. The prognostic value of ambulatory blood pressures // J. Am. Med. Assoc. <http://www.ncbi.nlm.nih.gov/pubmed?term=Sokolow%20%20AND%20JAMA%201983> - 1983. - Vol. 249, № 20. - P. 2792-2798.
18.
19. Dolan E <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Dolan%20E%22%5BAuthor%5D>., Stanton A <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Stanton%20A%22%5BAuthor%5D>., Thijs L <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Thijs%20L%22%5BAuthor%5D>. et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study // Hypertension <http://www.ncbi.nlm.nih.gov/pubmed?term=Dolan%20AND%20Hypertension%202005%3B%2046%281%29%3A%20156-161>. - 2005. - Vol. 46, № 1. - P. 156-161.
20.
21. Dolan E <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Dolan%20E%22%5BAuthor%5D>., Stanton A.V <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Stanton%20AV%22%5BAuthor%5D>., Thom S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Thom%20S%22%5BAuthor%5D>. et al.; ASCOT Investigators <http://www.ncbi.nlm.nih.gov/pubmed?term=%22ASCOT%20Investigators%22%5BCorporate%20Author%5D>. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients-an Anglo-Scandinavian cardiac outcomes trial substudy // J. Hypertens. <http://www.ncbi.nlm.nih.gov/pubmed?term=Dolan%20AND%20Hypertension%202009%3B%2027%284%29> - 2009. - Vol. 27, № 4. - P. 876-885.
22.
23. Messerli F.H <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Messerli%20FH%22%5BAuthor%5D>., Mancia G <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Mancia%20G%22%5BAuthor%5D>., Conti C.R <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Conti%20CR%22%5BAuthor%5D>. et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? // Ann. Intern. Med <http://www.ncbi.nlm.nih.gov/pubmed?term=Musserli%20AND%20Ann%20Intern%20Med%202006%3B%20144%2812%29%3A%20884-893>. - 2006. - Vol. 144, № 12. - P. 884-893.
24.
25. Williams B <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Williams%20B%22%5BAuthor%5D>., Lacy P.S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lacy%20PS%22%5BAuthor%5D>., Thom S.M <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Thom%20SM%22%5BAuthor%5D>. et al.; CAFE Investigators <http://www.ncbi.nlm.nih.gov/pubmed?term=%22CAFE%20Investigators%22%5BCorporate%20Author%5D>; Anglo-Scandinavian Cardiac Outcomes Trial Investigators <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Anglo-Scandinavian%20Cardiac%20Outcomes%20Trial%20Investigators%22%5BCorporate%20Author%5D>; CAFE Steering Committee and Writing Committee <http://www.ncbi.nlm.nih.gov/pubmed?term=%22CAFE%20Steering%20Committee%20and%20Writing%20Committee%22%5BCorporate%20Author%5D>. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study // Circulation. <http://www.ncbi.nlm.nih.gov/pubmed?term=Circulation%202006%3B%20113%3A%201213-1225> - 2006. - Vol. 113, № 9. - P. 1213-1225.
26.
27. Poulter N.R <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Poulter%20NR%22%5BAuthor%5D>., Dobson J.E <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Dobson%20JE%22%5BAuthor%5D>., Sever P.S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Sever%20PS%22%5BAuthor%5D>. et al.; ASCOT Investigators <http://www.ncbi.nlm.nih.gov/pubmed?term=%22ASCOT%20Investigators%22%5BCorporate%20Author%5D>. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) // J. Am. Coll. Cardiol. <http://www.ncbi.nlm.nih.gov/pubmed?term=Poulter%20AND%20JACC%202009%3B%2054%2813%29%3A%201154-61> - 2009. - Vol. 54, № 13. - P. 1154-1561.
28.
29. Dahlof B., Devereux R., Kjeldsen S. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol // Lancet. - 2002. - Vol. 359, № 9311. - P. 995-1003.
30.
31. Hansson L., Lindholm L.H., Niskanen L. et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial // Lancet. - 1999. - Vol. 353, № 9153. - P. 611-616.
32.
33. Messerli F.H <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Messerli%20FH%22%5BAuthor%5D>., Bangalore S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bangalore%20S%22%5BAuthor%5D>., Ruschitzka F <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ruschitzka%20F%22%5BAuthor%5D>. Angiotensin receptor blockers: baseline therapy in hypertension? // Eur. Heart J. <http://www.ncbi.nlm.nih.gov/pubmed?term=Messerli%20F.H.%2C%20Bandalore%20S.%2C%20Ruschitzka%20F.%20Eur%20Heart%20J%202009%3B%2030%2820%29%3A%202427-2430> - 2009. - Vol. 30, № 20. - P. 2427-2430.
34.
35. Strauss M.H <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Strauss%20MH%22%5BAuthor%5D>., Hall A.S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Hall%20AS%22%5BAuthor%5D>. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox // Circulation. <http://www.ncbi.nlm.nih.gov/pubmed?term=Angiotensin%20Receptor%20Blockers%20May%20Increase%20Risk%20of%20Myocardial%20Infarction%20Unraveling%20the%20ARB-MI%20Paradox> - 2006. - Vol. 114, № 8. - P. 838-854.
36.
37. Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial // Lancet. - 2004. - Vol. 363, № 9426. - P. 2022-2031.
38.
39. PROGRESS Collaborative Group. Randomised trial of perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke and transient ischemic attack // Lancet. - 2001. - Vol. 358, № 9287. - P. 1033-1041.
40.
41. The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study) // Lancet. - 2003. - Vol. 362, № 9386. -P. 782-788.
42.
43. Bertrand M.E <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bertrand%20ME%22%5BAuthor%5D>., Ferrari R <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ferrari%20R%22%5BAuthor%5D>., Remme W.J <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Remme%20WJ%22%5BAuthor%5D>. et al.; EUROPA Investigators <http://www.ncbi.nlm.nih.gov/pubmed?term=%22EUROPA%20Investigators%22%5BCorporate%20Author%5D>. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study // Am. Heart J <http://www.ncbi.nlm.nih.gov/pubmed?term=Bertrand%20M.E.%20Am%20Heart%20J%202010%3B%20159%3A%20795-802>. - 2010. - Vol. 159, № 5. - P. 795-802.
44.
45. Ferrari R <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ferrari%20R%22%5BAuthor%5D>. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril // Expert Rev. Cardiovasc. Ther <http://www.ncbi.nlm.nih.gov/pubmed/15723572>. - 2005. - Vol. 3, № 1. - P. 15-29.
46.
47. Jamerson K <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Jamerson%20K%22%5BAuthor%5D>., Weber M.A <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Weber%20MA%22%5BAuthor%5D>., Bakris G.L <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bakris%20GL%22%5BAuthor%5D>. et al; ACCOMPLISH Trial Investigators <http://www.ncbi.nlm.nih.gov/pubmed?term=%22ACCOMPLISH%20Trial%20Investigators%22%5BCorporate%20Author%5D>. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients // N. Engl. J. Med. <http://www.ncbi.nlm.nih.gov/pubmed?term=N%20Engl%20J%20Med%202008%3B%20359%3A%202417-28> - 2008. - Vol. 359, № 23. - P. 2417-2428.
48.
Review
For citations:
Karpov Y.A., Shubina A.T. The decrease of complication rate in hypertensives: Benefits of combined antihypertensive treatment by Perindopril and Amlodipine (adapted from the materials from the Annual Scientific Meeting of the European Society of Hypertension [ESH], 2011). "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2011;17(4):372-378. (In Russ.) https://doi.org/10.18705/1607-419X-2011-17-4-372-378
Views:
713
Email this article 